-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Gossamer Bio Analyst Ratings
Gossamer Bio Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/21/2022 | 25% | JP Morgan | → $17 | Initiates Coverage On | → Neutral |
09/19/2022 | 76.47% | Wedbush | → $24 | Initiates Coverage On | → Outperform |
08/18/2022 | 32.35% | Barclays | $12 → $18 | Maintains | Overweight |
08/10/2022 | 32.35% | Raymond James | $14 → $18 | Maintains | Outperform |
07/14/2022 | 2.94% | Raymond James | $10 → $14 | Maintains | Outperform |
05/11/2022 | 10.29% | SVB Leerink | $16 → $15 | Maintains | Outperform |
04/26/2022 | -11.76% | Barclays | $18 → $12 | Maintains | Overweight |
04/26/2022 | -26.47% | Raymond James | $19 → $10 | Maintains | Outperform |
04/18/2022 | 39.71% | Raymond James | → $19 | Initiates Coverage On | → Outperform |
04/06/2022 | 39.71% | UBS | → $19 | Initiates Coverage On | → Buy |
11/09/2021 | 17.65% | SVB Leerink | $15 → $16 | Maintains | Outperform |
08/10/2021 | 10.29% | SVB Leerink | $19 → $15 | Maintains | Outperform |
03/24/2021 | 83.82% | HC Wainwright & Co. | $24 → $25 | Reiterates | → Buy |
10/19/2020 | 10.29% | HC Wainwright & Co. | $31 → $15 | Maintains | Buy |
10/14/2020 | 47.06% | Cantor Fitzgerald | $33 → $20 | Maintains | Overweight |
10/13/2020 | 113.24% | SVB Leerink | $36 → $29 | Maintains | Outperform |
07/14/2020 | 142.65% | Cantor Fitzgerald | $25 → $33 | Reiterates | → Overweight |
06/29/2020 | 127.94% | HC Wainwright & Co. | → $31 | Initiates Coverage On | → Buy |
05/20/2020 | 164.71% | SVB Leerink | $27 → $36 | Reiterates | → Outperform |
04/22/2020 | 120.59% | Piper Sandler | → $30 | Initiates Coverage On | → Overweight |
02/27/2020 | 54.41% | Barclays | → $21 | Initiates Coverage On | → Overweight |
12/17/2019 | 83.82% | Cantor Fitzgerald | $34 → $25 | Reiterates | → Overweight |
12/06/2019 | 150% | Cantor Fitzgerald | → $34 | Initiates Coverage On | → Overweight |
12/03/2019 | 135.29% | B of A Securities | → $32 | Reinstates | → Buy |
10/30/2019 | 127.94% | Berenberg | → $31 | Initiates Coverage On | → Buy |
03/05/2019 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
03/05/2019 | — | SVB Leerink | Initiates Coverage On | → Outperform | |
03/05/2019 | 98.53% | Barclays | → $27 | Initiates Coverage On | → Overweight |
03/05/2019 | — | B of A Securities | Initiates Coverage On | → Buy |
Gossamer Bio Questions & Answers
The latest price target for Gossamer Bio (NASDAQ: GOSS) was reported by JP Morgan on September 21, 2022. The analyst firm set a price target for $17.00 expecting GOSS to rise to within 12 months (a possible 25.00% upside). 11 analyst firms have reported ratings in the last year.
The latest analyst rating for Gossamer Bio (NASDAQ: GOSS) was provided by JP Morgan, and Gossamer Bio initiated their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gossamer Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gossamer Bio was filed on September 21, 2022 so you should expect the next rating to be made available sometime around September 21, 2023.
While ratings are subjective and will change, the latest Gossamer Bio (GOSS) rating was a initiated with a price target of $0.00 to $17.00. The current price Gossamer Bio (GOSS) is trading at is $13.60, which is within the analyst's predicted range.
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/21/2022 | 25% | JP Morgan | → $17 | Initiates Coverage On | → Neutral |
09/19/2022 | 76.47% | Wedbush | → $24 | Initiates Coverage On | → Outperform |
08/18/2022 | 32.35% | Barclays | $12 → $18 | Maintains | Overweight |
08/10/2022 | 32.35% | Raymond James | $14 → $18 | Maintains | Outperform |
07/14/2022 | 2.94% | Raymond James | $10 → $14 | Maintains | Outperform |
05/11/2022 | 10.29% | SVB Leerink | $16 → $15 | Maintains | Outperform |
04/26/2022 | -11.76% | Barclays | $18 → $12 | Maintains | Overweight |
04/26/2022 | -26.47% | Raymond James | $19 → $10 | Maintains | Outperform |
04/18/2022 | 39.71% | Raymond James | → $19 | Initiates Coverage On | → Outperform |
04/06/2022 | 39.71% | UBS | → $19 | Initiates Coverage On | → Buy |
11/09/2021 | 17.65% | SVB Leerink | $15 → $16 | Maintains | Outperform |
08/10/2021 | 10.29% | SVB Leerink | $19 → $15 | Maintains | Outperform |
03/24/2021 | 83.82% | HC Wainwright & Co. | $24 → $25 | Reiterates | → Buy |
10/19/2020 | 10.29% | HC Wainwright & Co. | $31 → $15 | Maintains | Buy |
10/14/2020 | 47.06% | Cantor Fitzgerald | $33 → $20 | Maintains | Overweight |
10/13/2020 | 113.24% | SVB Leerink | $36 → $29 | Maintains | Outperform |
07/14/2020 | 142.65% | Cantor Fitzgerald | $25 → $33 | Reiterates | → Overweight |
06/29/2020 | 127.94% | HC Wainwright & Co. | → $31 | Initiates Coverage On | → Buy |
05/20/2020 | 164.71% | SVB Leerink | $27 → $36 | Reiterates | → Outperform |
04/22/2020 | 120.59% | Piper Sandler | → $30 | Initiates Coverage On | → Overweight |
02/27/2020 | 54.41% | Barclays | → $21 | Initiates Coverage On | → Overweight |
12/17/2019 | 83.82% | Cantor Fitzgerald | $34 → $25 | Reiterates | → Overweight |
12/06/2019 | 150% | Cantor Fitzgerald | → $34 | Initiates Coverage On | → Overweight |
12/03/2019 | 135.29% | B of A Securities | → $32 | Reinstates | → Buy |
10/30/2019 | 127.94% | Berenberg | → $31 | Initiates Coverage On | → Buy |
03/05/2019 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
03/05/2019 | — | SVB Leerink | Initiates Coverage On | → Outperform | |
03/05/2019 | 98.53% | Barclays | → $27 | Initiates Coverage On | → Overweight |
03/05/2019 | — | B of A Securities | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
09/21/2022 | 25% | 摩根大通 | → 17 美元 | 启动覆盖范围开启 | → 中立 |
09/19/2022 | 76.47% | Wedbush | → 24 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
08/18/2022 | 32.35% | 巴克莱 | 12 美元 → 18 美元 | 维持 | 超重 |
08/10/2022 | 32.35% | 雷蒙德·詹姆 | 14 美元 → 18 美元 | 维持 | 跑赢大盘 |
07/14/2022 | 2.94% | 雷蒙德·詹姆 | 10 美元 → 14 美元 | 维持 | 跑赢大盘 |
05/11/2022 | 10.29% | SVB Leerink | 16 美元 → 15 美元 | 维持 | 跑赢大盘 |
04/26/2022 | -11.76% | 巴克莱 | 18 美元 → 12 美元 | 维持 | 超重 |
04/26/2022 | -26.47% | 雷蒙德·詹姆 | 19 美元 → 10 美元 | 维持 | 跑赢大盘 |
04/18/2022 | 39.71% | 雷蒙德·詹姆 | → 19 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
04/06/2022 | 39.71% | 瑞银(UBS) | → 19 美元 | 启动覆盖范围开启 | → 购买 |
11/09/2021 | 17.65% | SVB Leerink | 15 美元 → 16 美元 | 维持 | 跑赢大盘 |
08/10/2021 | 10.29% | SVB Leerink | 19 美元 → 15 美元 | 维持 | 跑赢大盘 |
2021 年 3 月 24 日 | 83.82% | HC Wainwright & Co. | 24 美元 → 25 美元 | 重申 | → 购买 |
10/19/2020 | 10.29% | HC Wainwright & Co. | 31 美元 → 15 美元 | 维持 | 购买 |
10/14/2020 | 47.06% | 坎托·菲茨杰拉德 | 33 美元 → 20 美元 | 维持 | 超重 |
10/13/2020 | 113.24% | SVB Leerink | 36 美元 → 29 美元 | 维持 | 跑赢大盘 |
2020 年 7 月 14 日 | 142.65% | 坎托·菲茨杰拉德 | 25 美元 → 33 美元 | 重申 | → 超重 |
2020 年 6 月 29 日 | 127.94% | HC Wainwright & Co. | → 31 美元 | 启动覆盖范围开启 | → 购买 |
05/20/2020 | 164.71% | SVB Leerink | 27 美元 → 36 美元 | 重申 | → 跑赢大盘 |
2020 年 4 月 22 日 | 120.59% | 派珀·桑德勒 | → 30 美元 | 启动覆盖范围开启 | → 超重 |
02/27/2020 | 54.41% | 巴克莱 | → 21 美元 | 启动覆盖范围开启 | → 超重 |
12/17/2019 | 83.82% | 坎托·菲茨杰拉德 | 34 美元 → 25 美元 | 重申 | → 超重 |
12/06/2019 | 150% | 坎托·菲茨杰拉德 | → 34 美元 | 启动覆盖范围开启 | → 超重 |
2019 年 3 月 12 日 | 135.29% | B of A 证券 | → 32 美元 | 恢复 | → 购买 |
10/30/2019 | 127.94% | 贝伦贝格 | → 31 美元 | 启动覆盖范围开启 | → 购买 |
2019 年 5 月 3 日 | — | Evercore ISI 集团 | 启动覆盖范围开启 | → 跑赢大盘 | |
2019 年 5 月 3 日 | — | SVB Leerink | 启动覆盖范围开启 | → 跑赢大盘 | |
2019 年 5 月 3 日 | 98.53% | 巴克莱 | → 27 美元 | 启动覆盖范围开启 | → 超重 |
2019 年 5 月 3 日 | — | B of A 证券 | 启动覆盖范围开启 | → 购买 |
Gossamer Bio Questions & Answers
Gossamer Bio 问题与解答
The latest price target for Gossamer Bio (NASDAQ: GOSS) was reported by JP Morgan on September 21, 2022. The analyst firm set a price target for $17.00 expecting GOSS to rise to within 12 months (a possible 25.00% upside). 11 analyst firms have reported ratings in the last year.
摩根大通于2022年9月21日公布了高萨默生物(纳斯达克股票代码:GOSS)的最新目标股价。该分析公司将目标股价设定为17.00美元,预计GOSS将在12个月内上涨至17.00美元(可能上涨25.00%)。去年有11家分析公司公布了评级。
The latest analyst rating for Gossamer Bio (NASDAQ: GOSS) was provided by JP Morgan, and Gossamer Bio initiated their neutral rating.
高萨默生物(纳斯达克股票代码:GOSS)的最新分析师评级由摩根大通提供,高萨默生物启动了中性评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gossamer Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gossamer Bio was filed on September 21, 2022 so you should expect the next rating to be made available sometime around September 21, 2023.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Gossamer Bio的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月进行一次评级,因此每家公司每年应获得4个评级。Gossamer Bio的最后一次评级是在2022年9月21日提交的,因此您应该预计下一个评级将在2023年9月21日左右公布。
While ratings are subjective and will change, the latest Gossamer Bio (GOSS) rating was a initiated with a price target of $0.00 to $17.00. The current price Gossamer Bio (GOSS) is trading at is $13.60, which is within the analyst's predicted range.
尽管评级是主观的,而且还会发生变化,但最新的Gossamer Bio(GOSS)评级是启动的,目标股价为0.00美元至17.00美元。Gossamer Bio(GOSS)目前的交易价格为13.60美元,在分析师的预测区间内。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧